Erica DiNapoli

Erica DiNapoli is an Assistant Editor for OncLive®. She joined the company in 2020 and now assists in editing and publishing both videos and informational articles to the website; she also helps manage the social media platforms. Prior to joining MJH Life Sciences, she was a student at Monmouth University and held two marketing internships at United Teletech Financial Federal Credit Union and Trendsetter Media & Marketing.

Articles

Long-Term KEYNOTE-426 Data Support Pembrolizumab/Axitinib as Frontline Standard in Advanced RCC

July 9th 2020

Pembrolizumab plus axitinib continued to significantly improve efficacy over sunitinib in patients with previously untreated metastatic renal cell carcinoma, according to updated results from the phase 3 KEYNOTE-426 trial.

MK-6482 Showcases Promising Clinical Activity in VHL Disease–Associated RCC

July 8th 2020

Eric Jonasch, MD, on the favorable efficacy and tolerability of MK-6482 in patients with Von Hippel-Lindau disease–associated renal cell carcinoma.

Expert Expands on Emerging Developments in Metastatic TNBC

July 7th 2020

Hatem Soliman, MD, discusses new therapeutic approaches for patients with metastatic triple-negative breast cancer.

Trastuzumab Deruxtecan Shakes Up HER2-Mutated NSCLC Treatment Paradigm

July 7th 2020

Solange Peters, MD, discusses the promising clinical activity observed with trastuzumab deruxtecan in patients with HER2-mutated NSCLC, next steps for research, and other exciting lung cancer data.

Venetoclax/Azacitidine Slated as New Standard in Older Patients With AML Ineligible for Intensive Therapy

July 6th 2020

Courtney D. DiNardo, MD, MSCE, discusses the results of the study evaluating the combination of azacitidine plus venetoclax in elderly patients with AML.

Leonard Shares Significance of the Tazemetostat Approval in Follicular Lymphoma

July 6th 2020

John P. Leonard, MD, discusses the FDA approval of tazemetostat in patients with follicular lymphoma.

Atezolizumab/Radium-223 Combo Shows No Benefit in mCRPC, But Biomarker Work Planned

June 29th 2020

Michael J. Morris, MD, discusses the combination of atezolizumab and radium-223 dichloride, which did not demonstrate a clinical benefit in patients with metastatic castration-resistant prostate cancer.

Systematic Germline Genetic Testing Is Feasible in Veterans With Metastatic Prostate Cancer

June 29th 2020

Alexandra Sokolova, MD, discusses the implementation of systematic germline genetic testing in veterans with metastatic prostate cancer appeared to be feasible due to high consent rates, especially with direct oncologist involvement.

Pembrolizumab Continues to Show Modest Clinical Activity in Advanced Ovarian Cancer

June 23rd 2020

Pembrolizumab demonstrated modest clinical activity in patients with advanced recurrent ovarian cancer.

Saad Highlights Striking Survival Benefit With Apalutamide in nmCRPC

June 22nd 2020

The addition of apalutamide to androgen deprivation therapy, significantly improved overall survival and metastasis-free survival in patients with nonmetastatic castration-resistant prostate cancer.

Expert Elucidates the Role of Neoadjuvant Systemic Therapy in High-Risk Retroperitoneal Sarcoma

June 19th 2020

Neoadjuvant systemic therapy was found to show a modest benefit in patients with retroperitoneal sarcoma, and the tumor response could be used as an indicator of disease biology to predict survival outcomes after surgery.

Eggermont Elucidates Activity With Adjuvant Pembrolizumab in Resected Stage III Melanoma

June 8th 2020

Alexander Eggermont, MD, PhD, discusses the impact of the 3-year follow-up data from the phase 3 double-blind EORTC 1325/KEYNOTE-054 trial in high-risk stage III melanoma.